Analyst Matthew Caufield of H.C. Wainwright reiterated a Buy rating on 4D Molecular Therapeutics, retaining the price target of $36.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Matthew Caufield has given his Buy rating due to a combination of factors tied to 4D Molecular Therapeutics’ advancing gene therapy platform and pivotal wet AMD program. He highlights the completion of enrollment in the Phase 3 4FRONT-1 trial and the expected full enrollment of the global 4FRONT-2 study in 2026, viewing these as key de-risking milestones ahead of topline data in 2027 that could showcase robust efficacy and durability versus current anti-VEGF standards.
He also emphasizes that prior PRISM trial data showed substantial reductions in treatment burden across multiple wet AMD patient subsets, which he believes can translate favorably into the Phase 3 setting, particularly in treatment-naïve patients. Taken together with the potential for 4D-150 to deliver sustained visual acuity, retinal stability, and fewer injections while maintaining a solid safety profile, he sees the program as capable of reshaping the treatment paradigm and therefore maintains his Buy rating and $36 price target.
According to TipRanks, Caufield is a 5-star analyst with an average return of 13.9% and a 44.07% success rate. Caufield covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., FibroBiologics, Inc., and Akebia Therapeutics.
In another report released on May 8, Bank of America Securities also reiterated a Buy rating on the stock with a $29.00 price target.